Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide

被引:93
作者
Buechner, SA
Wernli, M
Harr, T
Hahn, S
Itin, P
Erb, P
机构
[1] Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland
[2] Univ Basel, Kantonsspital, Dept Dermatol, CH-4031 Basel, Switzerland
关键词
basal cell carcinoma; apoptosis; CD95; ligand; IFN-alpha;
D O I
10.1172/JCI119814
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Basal cell carcinoma (BCC) is the most common skin cancer in humans, and although metastasis rarely occurs, the tumor cells are nevertheless able to invade and destroy the surrounding tissue, Intralesional injection of IFN-alpha has been found to be highly effective in inducing BCC regression by an unknown mechanism, We show that in untreated patients, BCC cells express CD95 ligand, but not the receptor, which may allow tumor expansion by averting the attack of activated CD95 receptor-positive lymphoid effector cells, The CD95 ligand of BCC cells is functional as CD95-positive cells incubated on BCC cryosections become apoptotic and are lysed, In IFN-alpha-treated patients BCC cells express not only CD95 ligand but also CD95 receptor, whereas the peritumoral infiltrate that mainly consists of CD4+ T cells predominantly contains CD95 receptor and only few CD95 ligand-positive cells, Thus, in treated patients BCC most likely regresses by committing suicide through apoptosis induction via CD95 receptor-CD95 ligand interaction.
引用
收藏
页码:2691 / 2696
页数:6
相关论文
共 46 条
  • [11] CELL-DEATH MECHANISMS AND THE IMMUNE-SYSTEM
    GOLSTEIN, P
    OJCIUS, DM
    YOUNG, JDE
    [J]. IMMUNOLOGICAL REVIEWS, 1991, 121 : 29 - 65
  • [12] TREATMENT OF BASAL-CELL CARCINOMA WITH INTRALESIONAL INTERFERON
    GREENWAY, HT
    CORNELL, RC
    TANNER, DJ
    PEETS, E
    BORDIN, GM
    NAGI, C
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1986, 15 (03) : 437 - 443
  • [13] BIOLOGIC EFFECTS OF INTERFERONS
    GRESSER, I
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 95 (06) : S66 - S71
  • [14] FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE
    GRIFFITH, TS
    BRUNNER, T
    FLETCHER, SM
    GREEN, DR
    FERGUSON, TA
    [J]. SCIENCE, 1995, 270 (5239) : 1189 - 1192
  • [15] GROB JJ, 1988, LANCET, V1, P878
  • [16] MECHANISM AND BIOLOGICAL SIGNIFICANCE OF CD4-MEDIATED CYTOTOXICITY
    HAHN, S
    GEHRI, R
    ERB, P
    [J]. IMMUNOLOGICAL REVIEWS, 1995, 146 : 57 - 79
  • [17] Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
    Hahne, M
    Rimoldi, D
    Schroter, M
    Romero, P
    Schreier, M
    French, LE
    Schneider, P
    Bornand, T
    Fontana, A
    Lienard, D
    Cerottini, JC
    Tschopp, J
    [J]. SCIENCE, 1996, 274 (5291) : 1363 - 1366
  • [18] FAS AND ITS LIGAND IN A GENERAL MECHANISM OF T-CELL-MEDIATED CYTOTOXICITY
    HANABUCHI, S
    KOYANAGI, M
    KAWASAKI, A
    SHINOHARA, N
    MATSUZAWA, A
    NISHIMURA, Y
    KOBAYASHI, Y
    YONEHARA, S
    YAGITA, H
    OKUMURA, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) : 4930 - 4934
  • [19] REGRESSION IN BASAL-CELL CARCINOMA - AN IMMUNOHISTOCHEMICAL ANALYSIS
    HUNT, MJ
    HALLIDAY, GM
    WEEDON, D
    COOKE, BE
    BARNETSON, RSC
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1994, 130 (01) : 1 - 8
  • [20] PARTICIPATION OF TARGET FAS PROTEIN IN APOPTOSIS PATHWAY INDUCED BY CD4(+) TH1 AND CD8(+) CYTOTOXIC T-CELLS
    JU, ST
    CUI, HL
    PANKA, DJ
    ETTINGER, R
    MARSHAKROTHSTEIN, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (10) : 4185 - 4189